ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

11,451Medicare Part D Prescriptions Filled, Including Refills

Rank: 369 out of 4623

$566K Total Retail Price of All Prescriptions

Rank: 576 out of 4623

541 Patients Receiving at Least One Drug in Part D
42%Patients 65 Years and Older
89% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Texas
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

27% of this provider’s 541 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

4% of this provider’s 5,665 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$49 was the average price of a prescription from this provider, compared to $61 among peers.

Prescriptions per Patient

21 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Texas
HYDROCODONE-ACETAMINOPHEN 631 225 S3 1 3
LISINOPRIL 432 216 2 4
METFORMIN HCL 396 182 3 6
SIMVASTATIN 353 191 4 2
FUROSEMIDE 341 217 5 8
HYDROCHLOROTHIAZIDE 334 165 6 10
PRAVASTATIN SODIUM 333 123 7 11
LEVOTHYROXINE SODIUM 324 249 8 1
OMEPRAZOLE 293 136 9 7
AMLODIPINE BESYLATE 293 150 9 5
LISINOPRIL-HYDROCHLOROTHIAZIDE 287 131 11 19
POTASSIUM CHLORIDE 239 147 12 14
NEXIUM 228 62 13 17
CARVEDILOL 216 117 14 25
METOPROLOL TARTRATE 199 102 15 9
ATORVASTATIN CALCIUM 192 97 16 12
CYCLOBENZAPRINE HCL 172 37 R 17 53
MELOXICAM 163 87 18 27
ENALAPRIL MALEATE 151 86 19 41
TRAMADOL HCL 144 53 20 15
RANITIDINE HCL 130 64 21 47
ZOLPIDEM TARTRATE 124 46 22 18
JANUVIA 114 88 23 52
CRESTOR 113 56 24 20
TRAZODONE HCL 108 48 25 42
GLIPIZIDE 108 56 25 49
METOPROLOL SUCCINATE 107 36 27 13
WARFARIN SODIUM 106 47 28 24
GABAPENTIN 106 40 28 16
AZITHROMYCIN 100 43 30 33
LIPITOR 98 49 31 100
LANTUS 97 79 32 44
NIFEDIPINE ER 95 48 33 97
GLYBURIDE 92 68 R 34 59
INSULIN SYRINGE 84 42 35 85
SERTRALINE HCL 79 55 36 26
CLONIDINE HCL 78 20 37 40
NAPROXEN 77 46 38 63
CITALOPRAM HBR 68 24 39 23
GLYBURIDE-METFORMIN HCL 68 52 R 39 56
SPIRONOLACTONE 65 38 41 77
AMITRIPTYLINE HCL 63 32 R 42 69
PROAIR HFA 63 23 42 64
LYRICA 60 20 44 66
DOXAZOSIN MESYLATE 58 30 45 98
ATENOLOL 57 33 46 28
PAROXETINE HCL 57 34 46 78
GEMFIBROZIL 56 31 48 94
TAMSULOSIN HCL 52 47 49 29
DIOVAN 50 32 50 39
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 19, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.